Global Divalproex Sodium Market is segmented By Application (Epilepsy and Migraine Headaches, Manic Depressive Illness, Others), By Dosage form (Tablet, Capsule, Syrup), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030
Divalproex Sodium Market Overview
The Global "Divalproex Sodium Market" is expected to reach at a high CAGR during the forecast period (2023-2030).
Divalproex sodium is an anti-epileptic drug approved by Food and Drug Administrator (FDA) used to treat migraine headaches, manic episodes of bipolar disorders, and certain types of seizures. It is known for its anticonvulsant properties for the treatment of epilepsy.
Divalproex Sodium Market Scope
|
Metrics |
Details |
|
Market CAGR |
High |
|
Segments Covered |
By Application, By Dosage form, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Know More Insights - Download Sample
Divalproex Sodium Market Dynamics
The divalproex sodium market growth is driven by the growing prevalence of bipolar disorders, increasing patient pool with epilepsy and migraine headaches, and growing government initiatives, and increasing research and development for the introduction of new products.
The increasing prevalence of bipolar disorders around the globe is expected to drive the growth in the forecast period
The increasing prevalence of bipolar disorders around the globe is propelling the divalproex sodium market growth. For instance, according to a study done by National Alliance on Mental Illness in 2017, the average age-of-onset of bipolar disorder is about 25, but it can occur in the teens, or more uncommonly, in childhood. The condition affects men and women equally, with about 2.8% of the U.S. population diagnosed with bipolar disorder and nearly 83% of cases classified as severe.
Increasing patient pool with epilepsy and migraine headaches is expected to drive the growth in the forecast period
The rising patient pool worldwide affected with epilepsy and migraine headaches is expected to boost demand for the divalproex sodium market significantly. For instance, according to the World Health Organization 2018 key facts, around 50 million people were globally affected with epilepsy, making it one of the most common neurological diseases, and around 80% of the people with epilepsy live in low- and middle-income countries.
According to the Migraine Trust Facts and Figures estimates, the global prevalence of migraine was 14.7% for the year 2013, that’s around 1 in 7 people. Furthermore, increasing awareness regarding diseases and various government initiatives to prevent head migraines is expected to propel the divalproex sodium market size.
Increasing adverse effects of divalproex sodium are likely to hinder the market growth
The FDA gave a black boxed warning due to the hepatotoxicity, pancreatitis, and high fetal risk associated with the use of divalproex sodium tablets and other known adverse reactions such as congenital disabilities, neurobehavioral adverse effects, and suicidal behavior are expected to restrain the divalproex sodium market growth.
Divalproex Sodium Market Industry Analysis
COVID-19 Impact Analysis
The COVID-19 pandemic has been continuing to transform the growth of various markets, the immediate impact of the outbreak is varied. While a few industries registered a drop in demand, numerous other markets may continue to remain unscathed and show promising growth opportunities. Initially, the outbreak of COVID-19 showed an impact on the divalproex sodium market by directly affecting its production, creating supply chain disruptions, and creating a financial impact on firms due to social distancing and lockdown measures taken by the government. However, demand for divalproex sodium is expected to rise at a considerable pace in the coming years.
Divalproex Sodium Market Segment Analysis
The tablet segment is expected to hold the largest share in this market segment
Divalproex sodium oral tablet is available in brand names Depakote ER and Depakote. Divalproex sodium is also used in various combinational therapies. The recommended initial dosage of Depakote for the treatment of bipolar disorders is 750 mg daily, whereas, for complex partial seizures, the initial dosage starts with 10 to 15 mg/kg/day. Also, recommended starting dose for migraine headache is 250 mg twice daily to achieve a therapeutic response. Divalproex sodium extended-release tablets are valproate and are indicated for treating acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.
Epilepsy and migraine headaches segment are expected to hold the largest share in this market segment
Epilepsy is one of the most common nervous system disorders which causes seizures. When there is an enduring predisposition to seizures, it is called epilepsy. It can affect people of any age, from children to adults of all races and backgrounds. For instance, seizures and epilepsy are some of the challenging health issues faced by many children. An epileptic seizure is said to be an abnormal electrical activity in your brain. It is a state of neurological activity that feels like a shock wave traveling through the brain, and the recurrence of these repetitive unprovoked seizures is called epilepsy.
Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. As per a 2018 article published by the American Academy of Family Physicians (AAFP), more than 15% of adults in the United States had experienced a migraine episode or a severe headache within three months. According to Migraine Research Foundation, 12% of the population, including children, suffers from migraines and around 18% of American women, 6% of men, and 10% of children experience migraines.
The rise in people getting affected by epilepsy and migraine headaches is projected to account for the largest market share during the forecast period. Epilepsy is triggered due to certain health conditions like brain tumors, strokes, brain infections, neurological defects, lack of oxygen to the brain, hyperpyrexia, etc. Traumatic head and brain injuries, specific genetic conditions, smoking, and drinking alcohol also led to epilepsy. At the same time, migraine is triggered due to hormonal changes, emotional triggers such as stress, depression, anxiety, Dietary factors like alcohol, caffeine, medications, and environmental factors.
In the present scenario, the living styles of people have induced anxiety and stress in their daily life due to which patient pool getting affected by epilepsy and migraine headaches are expected to increase during the forecast period and contribute as a driving factor divalproex sodium market.
The retail pharmacies segment is expected to hold the largest share in this market segment
The retail pharmacies segment is expected to dominate during the forecast period. Divalproex sodium drugs are easily, readily available in retail pharmacies as generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost the market growth.
Divalproex Sodium Market Geographical Share
North America region holds the largest market share of the global divalproex sodium market
In the North American region, the United States divalproex sodium market holds the major share. Rising government initiatives and increasing research and development for the introduction of novel products are expected to aid in the growth of the divalproex sodium market in the region. For instance, according to the Centers for Disease Control and Prevention, approximately 3 million adults and 470,000 children in the United States have epilepsy. According to a survey of 11 countries performed by Therapeutic Advances in Psychopharmacology, 2018, the lifetime prevalence of bipolar disorder was 2.4%, and out of that, 1% of prevalence was found in the United States, which is higher than other countries in the survey.
Divalproex Sodium Market Companies and Competitive Landscape
The global divalproex sodium market is moderately competitive with the presence of global companies. Some of the key players which are contributing to the growth of the market include Zydus Cadila Pharmaceuticals, Inc., AbbVie Inc., Mylan N.V., Abbott Laboratories, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Orchid Chemicals & Pharmaceuticals Limited, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Abbott Laboratories. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in 2019 Lupin received the approval for divalproex sodium extended-release tablets USP 250 mg and 500 mg from the US FDA for commercializing generic equivalent of Depakote extended-release Tablets, 250 mg, and 500 mg, of AbbVie.
Divalproex Sodium Market Key Companies to Watch
Zydus Cadila Pharmaceuticals, Inc
Overview: Zydus Cadila, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.
Product Portfolio: The company portfolio includes New Chemical Entities, Biologics, Vaccines.
Key developments: In 2017, Zydus Cadila acquired Sentynl Therapeutics, a U.S.-based pharma company specialized in the marketing of products in the pain management segment.
The global divalproex sodium market report would provide access to an approx. 61 market data tables, 52 figures, and 180 pages.
